363 related articles for article (PubMed ID: 16192604)
1. Design issues of randomized phase II trials and a proposal for phase II screening trials.
Rubinstein LV; Korn EL; Freidlin B; Hunsberger S; Ivy SP; Smith MA
J Clin Oncol; 2005 Oct; 23(28):7199-206. PubMed ID: 16192604
[TBL] [Abstract][Full Text] [Related]
2. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
3. Design issues in randomized phase II/III trials.
Korn EL; Freidlin B; Abrams JS; Halabi S
J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
[TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trials: a long-term investment with promising returns.
Sharma MR; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
[TBL] [Abstract][Full Text] [Related]
6. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
Neven A; Mauer M; Hasan B; Sylvester R; Collette L
J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
[TBL] [Abstract][Full Text] [Related]
7. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
Mayo MS; Mahnken JD; Soong SJ
J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
[TBL] [Abstract][Full Text] [Related]
8. Selecting promising treatments in randomized Phase II cancer trials with an active control.
Cheung YK
J Biopharm Stat; 2009; 19(3):494-508. PubMed ID: 19384691
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II designs.
Rubinstein L; Crowley J; Ivy P; Leblanc M; Sargent D
Clin Cancer Res; 2009 Mar; 15(6):1883-90. PubMed ID: 19276275
[TBL] [Abstract][Full Text] [Related]
10. A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.
Grayling MJ; Dimairo M; Mander AP; Jaki TF
J Natl Cancer Inst; 2019 Dec; 111(12):1255-1262. PubMed ID: 31218346
[TBL] [Abstract][Full Text] [Related]
11. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
12. A review of phase II trial designs for initial marker validation.
Mandrekar SJ; An MW; Sargent DJ
Contemp Clin Trials; 2013 Nov; 36(2):597-604. PubMed ID: 23665336
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
14. Designs for randomized phase II clinical trials with two treatment arms.
Hou W; Chang MN; Jung SH; Li Y
Stat Med; 2013 Nov; 32(25):4367-79. PubMed ID: 23630064
[TBL] [Abstract][Full Text] [Related]
15. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
16. [Phases 0, 1 and 2 oncology clinical trials: current questions].
Penel N; Fournier C; Stéphanie C
Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
[TBL] [Abstract][Full Text] [Related]
17. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
[TBL] [Abstract][Full Text] [Related]
18. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
19. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
[TBL] [Abstract][Full Text] [Related]
20. Using historical lesion volume data in the design of a new phase II clinical trial in acute stroke.
Whitehead J; Bolland K; Valdès-Márquez E; Lihic A; Ali M; Lees K;
Stroke; 2009 Apr; 40(4):1347-52. PubMed ID: 19228847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]